Connect with us

Technology

HDT Bio to Help Spearhead RNA Vaccine Development in National Pandemic Preparedness Initiative

Published

on

HDT bio’s Rapid-Response Roadmap for RNA vaccines (R4) project granted a five-year subaward for $2M per year

SEATTLE, Sept. 17, 2024 /PRNewswire/ — HDT Bio Corp., a clinical-stage biopharmaceutical company specializing in advanced RNA vaccine technologies, is proud to announce its pivotal role in PROVIDENT (Prepositioning Optimized Strategies for Vaccines and Immunotherapeutics Against Diverse Emerging Infectious Threats), a national consortium led by Albert Einstein College of Medicine and funded by the National Institute of Allergy and Infectious Diseases (NIAID) as part of the Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network.

HDT Bio will focus on developing “road maps” for the rapid creation of RNA vaccines against pathogens with pandemic potential, harnessing the company’s proprietary AMPLIFY™ self-amplifying replicon RNA (repRNA) platform and LION™ nanoparticle delivery system. The combination of these two technologies offers increased vaccine potency, durability, and stability, while simplifying production—critical features for addressing emerging infectious threats quickly and effectively.

“We are excited to contribute our expertise in RNA vaccine technologies to the PROVIDENT consortium,” said Steve Reed, Ph.D., Chief Executive Officer of HDT Bio. “Our AMPLIFY™ and LION™ platforms have demonstrated their ability to rapidly generate potent, durable immune responses with a favorable safety profile. These innovations will be essential in preparing for future pandemics, where speed and flexibility in vaccine development will save lives.”

As part of the PROVIDENT initiative, HDT Bio will develop a comprehensive strategy to create RNA vaccines capable of targeting pathogens across multiple viral families, focusing particularly on rapid adaptability to emerging “virus X” scenarios. This aligns with PROVIDENT’s broader goals of safeguarding public health by advancing platforms that can be quickly tailored to respond to novel viral threats.

“It is currently unknown if the state-of-the-art approaches used to design vaccine antigens for traditional vaccine technologies can simply be co-opted for use in RNA vaccine technologies,” said Jesse Erasmus, Ph.D., who is the principal investigator on the subaward. “In our project, Rapid-Response Roadmap for RNA vaccines, HDT Bio will address this unknown while generating prototype vaccine candidates for 8 different viruses across 3 virus families of pandemic potential, collaborating with other member institutions of PROVIDENT to design and characterize antigens using structure-guided and high-throughput mutagenesis approaches.”

“We will also evaluate safety and immunogenicity against a diverse panel of viruses, and characterize efficacy in high-containment,” Dr. Erasmus added.

The additional key contributors to these efforts at HDT Bio are:

Amit Khandhar, Ph.D., Director of FormulationsTaishi Kimura, Ph.D., Senior ScientistE. Taylor Stone, Ph.D., Scientist

HDT Bio will work with 12 teams in academia and government alongside 3 other projects titled, 1) “Discovery and dissection of virus-host interactions and pathogenetic mechanisms”, 2) “Antigen design and immunological evaluation”, and 3) Mining human antibody responses to inform vaccine and therapeutic design”. More details on collaborating institutions and their key researchers can be found in Albert Einstein College of Medicine’s description of the parent award.

HDT Bio’s LION™/repRNA platform builds on the company’s pioneering work in vaccine development, notably including emergency use authorizations for its vaccine during the COVID-19 pandemic. The company’s innovative approach to RNA vaccine delivery, particularly through its LION™ nanotechnology, enhances the safety and efficacy of RNA-based vaccines while maintaining crucial logistical benefits such as refrigeration stability and simplified manufacturing.

“Our role in PROVIDENT exemplifies HDT Bio’s mission to make RNA vaccines a cornerstone of future pandemic preparedness,” added Dr. Reed. “By working in concert with academic, government, and industry partners, we aim to provide the tools needed to address unknown viral threats quickly and efficiently.”

For more information on HDT Bio’s AMPLIFY™ and LION™ platforms, visit www.hdt.bio.

About HDT Bio

HDT Bio is a Seattle-based, clinical-stage biopharmaceutical development company. With core technology and expertise in nucleic acid formulation, the company develops products that seek to harness host-directed immune responses. HDT Bio’s work focuses on infectious disease and oncology vaccines and therapeutics through early-stage collaborations with partners worldwide. The company’s vaccine platforms combine formulation and adjuvant ingredients to stabilize and deliver RNA to the immune system to stimulate responses. HDT Bio’s repRNA/LION™ was the first self-amplifying RNA vaccine platform to ever receive a regulatory authorization.

View original content to download multimedia:https://www.prnewswire.com/news-releases/hdt-bio-to-help-spearhead-rna-vaccine-development-in-national-pandemic-preparedness-initiative-302250815.html

SOURCE HDT Bio Corp.

Continue Reading

Technology

How to Go 2x Long Anthropic (ANT): Leverage Shares by Themes Explains ANUU, the 2x Leveraged Anthropic ETF Launching Monday

Published

on

By

Following Anthropic’s $83-per-share IPO pricing and Nasdaq trading debut at $111.50-per-share on November 19, 2026, Leverage Shares by Themes outlines how investors can gain long exposure to Anthropic stock (ANT), and where its planned 2X Long Anthropic ETF (ANUU) fits into the investment landscape.

GREENWICH, Conn., Nov. 21, 2026 /PRNewswire/ — Leverage Shares by Themes today published a step-by-step guide for investors looking to invest in Anthropic stock following the company’s highly anticipated initial public offering. Anthropic, PBC priced its IPO at $83.00 per share on November 18, 2026, above its initially proposed range of $70 to $78, with the offering totaling approximately $81.3 billion. The company’s Class A common stock began trading on Nasdaq under the ticker ANT on November 19, opening at $111.50 per share. With Anthropic now publicly traded, investors can purchase shares through brokerage accounts, while those seeking leveraged exposure can explore the planned Leverage Shares 2X Long Anthropic Daily ETF (ANUU).

How to Buy Anthropic Stock (ANT) Now That It Is Trading on Nasdaq
Following its IPO on November 19, 2026, investors can buy Anthropic (ANT) shares through a brokerage account that offers Nasdaq-listed stocks.

Step 1: Find Anthropic Stock (ANT) Through Your Brokerage

Search for Anthropic under the ticker ANT in your brokerage account. Investors no longer need to request an IPO allocation, as shares are now available for purchase on the open market during regular trading hours.

Step 2: Check the Current Share Price

Anthropic’s market price may differ significantly from its $83.00 IPO price and can fluctuate throughout the trading day. Review the latest ANT share price before placing an order.

Step 3: Choose How to Buy ANT Shares

Investors can place a market order to buy at the prevailing market price or use a limit order to specify the maximum price they are willing to pay. Given the potential volatility of newly listed stocks, investors should consider the risks of each order type before trading.

Can You Get 2X Long Exposure to Anthropic Stock?
Yes, once it launches: the Leverage Shares 2X Long Anthropic Daily ETF (ANUU) will seek daily investment results, before fees and expenses, corresponding to 200% (2X) of the daily performance of Anthropic common stock.

ANUU is not a way to buy into the IPO itself. The Fund does not take part in the offering and does not hold Anthropic shares. It is designed for knowledgeable investors who want to take a bullish daily view on Anthropic and who monitor their positions actively. Investors with a bearish daily view can use ANDD (2X short) or ANSS (1X short) once they launch.

ANUU, ANDD and ANSS are not yet trading. Their first trading date on Cboe is this coming Monday, November 23, 2026.

Ticker

ETF Name

Underlying
Asset

Exchange

Expense
Ratio

ANUU

Leverage Shares 2X Long Anthropic Daily ETF

Anthropic

Cboe

0.75 %

ANDD

Leverage Shares 2X Short Anthropic Daily ETF

Anthropic

Cboe

0.75 %

ANSS

Leverage Shares 1X Short Anthropic Daily ETF

Anthropic

Cboe

0.99 %

“Most of the questions we are getting this week are practical ones: what the ticker is, when the stock opens and how to buy it,” said Paul Marino, Chief Revenue Officer, Themes ETFs. “We want investors to have clear answers first, and to understand that ANUU is a daily 2X tool for active traders, not a substitute for owning Anthropic shares.”

Frequently Asked Questions

What Is Anthropic’s Stock Ticker?
Anthropic’s Class A common stock is expected to trade on the Nasdaq Global Select Market under the ticker ANT. ANUU, ANDD and ANSS are Leverage Shares ETF tickers, not Anthropic’s.

Is ANUU the Same as Buying Anthropic Stock?
No. ANUU will seek 2X the daily move of Anthropic stock, before fees and expenses. It does not give its investors Anthropic shares or shareholder voting rights, and its returns over periods longer than one day can differ significantly from 2X the stock’s return.

For more on how the three ETFs work, see the Leverage Shares research team’s guide, Anthropic Leveraged ETFs Explained: Long And Short 

Fund pages: 2X Long Anthropic ETF (ANUU) | 2X Short Anthropic ETF (ANDD) | 1X Short Anthropic ETF (ANSS)

About Themes ETFs

Themes ETFs is a provider of thematic and single-stock leveraged ETFs, focused on delivering innovative, cost-efficient investment tools that allow investors to access the companies and trends shaping the future. Through its Leverage Shares platform, Themes ETFs offers daily leveraged and inverse ETF strategies designed for sophisticated investors and active traders.

For more information, visit www.themesetfs.com and www.leverageshares.com.

INVESTMENT INVOLVES SIGNIFICANT RISK. Funds do not invest directly in the underlying stock. As with any investment, there is a risk that you could lose all or a portion of your investment in the Funds.

An investor should carefully consider a Fund’s investment objective, risks, charges, and expenses before investing. A Fund’s prospectus and summary prospectus contain this and other information about Themes ETFs. To obtain a Fund’s prospectus and summary prospectus call 866-584-3637. A Fund’s prospectus and summary prospectus should be read carefully before investing.

Newly launched Funds have risks associated with a limited operating history.

Because of daily rebalancing and the compounding of each day’s return over time, the return of a Fund for periods longer than a single day will be the result of each day’s returns compounded over the period, which will very likely differ from the stated multiple or inverse multiple of the return of the underlying stock over the same period. The Funds are not suitable for all investors. The Funds are designed to be utilized only by knowledgeable investors who understand the potential consequences of seeking daily leveraged or inverse investment results, understand the risks associated with the use of leverage and inverse exposure, as applicable, and are willing to monitor their portfolios frequently. The Funds are not intended to be used by, and are not appropriate for, investors who do not intend to actively monitor and manage their portfolios.

Under the Investment Advisory Agreement between the Adviser and the Trust, on behalf of the Funds (the “Investment Advisory Agreement”), the Adviser has agreed to pay all expenses of the Funds, except for the fee paid to the Adviser pursuant to the Investment Advisory Agreement, interest charges on any borrowings, taxes, brokerage commissions and other expenses incurred in placing orders for the purchase and sale of securities and other investment instruments, acquired fund fees and expenses, accrued deferred tax liability, extraordinary expenses, and distribution (12b-1) fees and expenses.

Past performance does not guarantee future results.

INVESTMENT RISKS: Investing in the Funds involves a high degree of risk. As with any investment, there is a risk that you could lose all or a portion of your investment in the Funds.

Investment in leveraged and inverse products may be subject to higher volatility. The Funds do not directly invest in the underlying stock. An investment in a Fund involves risk, including the possible loss of principal. The Funds are non-diversified and include risks associated with concentrating investments in a particular industry, sector, or geographic region, which can result in increased volatility. The use of derivatives such as futures contracts and swaps is subject to market risks that may cause their price to fluctuate over time.

Risks of the Funds include effects of Compounding and Market Volatility Risk, Inverse Risk, Market Risk, Counterparty Risk, Rebalancing Risk, IntraDay Investment Risk, Daily Index Correlation Risk, Other Investment Companies (including ETFs) Risk, and risks specific to the securities of the Underlying Stock and the sector in which it operates. These and other risks can be found in the prospectus.

For periods longer than a single day, the Funds may lose money even if Anthropic’s stock price remains flat or moves in a direction consistent with a Fund’s investment objective. An investor could lose the full principal value of their investment in the Leverage Shares 2x Long Anthropic Daily ETF (ANUU) if Anthropic’s stock price declines by more than 50% in a single trading day, or in the Leverage Shares 2x Short Anthropic Daily ETF (ANDD) if Anthropic’s stock price increases by more than 50% in a single trading day. The Leverage Shares 1x Short Anthropic Daily ETF (ANSS) also carries the risk of substantial or total loss if Anthropic’s stock price rises significantly.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. The market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (NBBO) as of the time the ETF calculates current NAV per share, and do not represent the returns you would receive if you traded shares at other times. NAVs are calculated using prices as of 4:00 PM Eastern Time. Indices are unmanaged and do not include the effect of fees, expenses, or sales charges. One cannot invest directly in an index.

This information is not an offer to sell or a solicitation of an offer to buy shares of any Funds to any person in any jurisdiction in which an offer, solicitation, purchase or sale would be unlawful under the securities laws of such jurisdiction.

Themes Management Company LLC serves as an adviser to the Themes ETFs Trust. The Funds are distributed by ALPS Distributors, Inc. (1290 Broadway, Suite 1000, Denver, Colorado 80203). ALPS is not affiliated with Anthropic or any other mentioned entity. Client brokerage services are not offered by ALPS. Please see third-party sites for more information about any mentioned services.

Themes ETFs are not sponsored, endorsed, issued, sold, or promoted by Anthropic, nor does Anthropic make any representations regarding the advisability of investing in Themes ETFs. Neither ALPS Distributors, Inc., Themes Management Company LLC nor Themes ETFs are affiliated with Anthropic.

Themes Management Company LLC and Leverage Shares are affiliates that are under common control. Themes Management Company LLC and Leverage Shares have entered into a licensing agreement in which Leverage Shares licenses the trademark LEVERAGE SHARES to Themes Management Company LLC for use in financial services in the United States.

View original content:https://www.prnewswire.com/news-releases/how-to-go-2x-long-anthropic-ant-leverage-shares-by-themes-explains-anuu-the-2x-leveraged-anthropic-etf-launching-monday-302947477.html

SOURCE Themes ETFs

Continue Reading

Technology

Managed IT Expert Lionel Fermin Explains When a Business Needs a Fractional CIO

Published

on

By

Lionel Fermin examines when growing businesses may need technology leadership for planning, security, spending, and long-term technology decisions.

 HOBBS, N.M., Nov. 21, 2026 /PRNewswire/ — When does a business need a Fractional CIO? A HelloNation article featuring insights from Managed IT Expert Lionel Fermin of GlobaTech Solutions in Hobbs, New Mexico, explains when businesses may benefit from experienced technology leadership.

The HelloNation article explains that technology decisions often become more complicated as a business grows. New employees, software, equipment, and security risks can create challenges that basic technical support may not address. At that point, business leaders may need broader guidance about how technology supports the organization.

The article describes a Fractional CIO as someone who provides technology leadership without serving as a full-time executive. While technical support typically focuses on fixing problems and keeping systems working, this role considers how technology decisions affect employees, customers, security, costs, and future business needs.

This broader perspective can become important when several technology projects compete for attention. The article notes that businesses may recognize the need for improvements without knowing which ones should come first. Fractional CIO services can help prioritize projects according to risk, cost, and business value.

Technology planning is another major part of the role. Instead of waiting for systems or equipment to fail, the article explains that companies can prepare for equipment replacements, software changes, security improvements, and growth. Identifying major expenses early can also give leaders more time to compare options and prepare budgets.

Cybersecurity can create another need for technology leadership. The article notes that a security incident can interrupt operations, create financial losses, and affect customer relationships. Executive technology guidance can help leaders understand cybersecurity risks in business terms and determine which concerns deserve the most attention.

The article also describes how Fractional CIO services can assist with customer or industry security requirements. Businesses may receive questionnaires or requests to demonstrate specific protections. Technology leadership can help identify gaps, organize responses, and provide a clearer view of existing security practices.

Growth can also signal the need for more structured technology guidance. Systems that worked for a small team may become strained as a company adds employees. The article explains that a technology strategy can help businesses prepare for greater demands on software, networks, security, and employee access.

Vendor management is another area where stronger oversight may be useful. Companies often work with separate providers for software, internet service, phones, security, and technical support. The article notes that reviewing vendor costs, contracts, performance, and responsibilities can help reduce duplication and clarify who handles important technology needs.

Major business changes can also increase the need for planning. Opening a new office, replacing software, or hiring many employees may require coordination among leadership, employees, vendors, and technical teams. Managed IT Expert Lionel Fermin’s insights featured in the article address how technology leadership can help keep these decisions connected to broader company goals.

The article notes that not every company needs a full-time technology executive. Smaller businesses may instead need experienced guidance for certain projects or a limited number of hours. Warning signs can include rising technology costs, repeated cybersecurity concerns, unsuccessful projects, or leaders spending too much time managing technology questions.

A lack of shared planning may provide another warning sign. When departments make separate technology decisions, businesses can face higher costs, security gaps, and software problems. The article explains that a shared technology strategy can provide clearer direction across the organization.

Ultimately, the article explains that the value of a Fractional CIO centers on planning and leadership rather than daily troubleshooting. Strong technology guidance can help businesses organize decisions about systems, security, spending, growth, and long-term needs.

When a Business Needs a Fractional CIO features insights from Lionel Fermin, Managed IT Expert of Hobbs, New Mexico, in HelloNation.

About HelloNation
HelloNation is America’s Good News Network, a premier media platform built on the idea that good news travels faster when real people tell real stories. Through its community-focused publications and innovative “edvertising” approach, HelloNation delivers content that informs, inspires, and spotlights the leaders making a meaningful impact in their communities.

View original content to download multimedia:https://www.prnewswire.com/news-releases/managed-it-expert-lionel-fermin-explains-when-a-business-needs-a-fractional-cio-302947167.html

SOURCE HelloNation

Continue Reading

Technology

HEARTBOT AI Wins Chunghwa Telecom Special Award at Meet Neo Star 2026

Published

on

By

Named to the top 30 from more than 200 startups, AnyInsight won over judges with its zero-trust approach to AI governance

TAIPEI, Nov. 22, 2026 /PRNewswire/ — HEARTBOT AI has won the Chunghwa Telecom Special Award at Meet Neo Star 2026, the startup competition held during the Meet Taipei Startup Festival. CEO Nathan Yen pitched AnyInsight, the company’s enterprise AI security and governance platform, at the Meet Neo Star Demo Show Final on November 20, showing judges how companies can expand their use of AI agents without losing control of their data.

Alongside the judges’ awards, sponsors selected startups from the top 30 for their own prizes. HEARTBOT AI received the Chunghwa Telecom Special Award from Chunghwa Telecom (CHT), which includes priority eligibility for the final selection of the CHT 5G Accelerator Batch 9, CHT hicloud credits and opportunities to connect and collaborate with CHT business units.

Meet Taipei ran November 19 to 21 at Taipei Expo Park and drew more than 550 startups from 23 countries, its largest edition to date. In October, AnyInsight also received the ASOCIO Global Business Service Award.

Companies Want AI Agents, and Proof They Are Under Control

AI is moving beyond chat toward agents that read data, call internal systems and complete multistep tasks on their own. That changes what companies ask. The question is no longer which AI tools to use, but who can use them, what data they touch and what the agents actually did.

The gaps are already showing. Employees use personal AI accounts for work, leaving no company record. Agents built by individual teams run without IT’s knowledge, sometimes long after the people who built them have left. When auditors ask for AI usage records, teams spend weeks pulling them together by hand.

Regulation is adding pressure. The transparency obligations in Article 50 of the EU AI Act began applying in August 2026, and for Taiwanese companies that operate internationally, AI governance is now part of day-to-day operations.

One Platform for Models, Agents and Automated Workflows

AnyInsight is a zero-trust enterprise AI security and governance platform. Companies can build agents and automated workflows in a single environment, drawing on over 20 leading cloud models, 350-plus ready-to-use AI agents and more than 500 application connectors.

Every AI interaction passes through a zero-trust generative AI firewall, which uses context-aware semantic analysis to detect personal, financial and health data as well as cloud credentials, and can alert on, block or mask that content in real time. Before an agent calls a tool through the Model Context Protocol (MCP), AnyInsight checks policy and authorizes access by role under the principle of least privilege. High-risk actions require human approval, and every event is logged as exportable audit evidence.

AnyInsight Edge Takes Governance On-Premises

On November 12, HEARTBOT AI announced AnyInsight Edge, which extends the same governance to on-premises environments and AI servers. Many companies bound by data residency rules or regulation have already deployed private large language models, only to find them stuck as internal chatbots with no access to core systems such as ERP, MES and CRM.

Edge ships as a container, needs no GPU and can run in a company’s data center or integrate with an AI server’s operating system. A single control plane manages policy centrally and enforces it consistently across cloud and on-premises environments. On-premises models such as Gemma and Mistral get access to AnyInsight’s agents, automated workflows and connectors, while AI conversations, transferred data and audit logs can stay in-house.

“Companies stopped asking whether to use AI a while ago,” said Nathan Yen, CEO of HEARTBOT AI. “What holds them back is that once agents multiply, nobody can say for sure what data they touched or what they did. AnyInsight gives every AI interaction and every agent action an owner and a record. Once companies can see that, they’re willing to put AI into their core operations.”

“Recognition from the Meet Neo Star judges means a lot to a startup working on AI governance,” Yen said. “A growing number of companies now treat control as a condition for adopting AI, and that’s the problem we work on every day.”

About HEARTBOT AI

HEARTBOT AI develops trustworthy, high-assurance enterprise AI solutions. Its flagship platform, AnyInsight, is a zero-trust enterprise AI security and governance platform with a built-in generative AI firewall, role-based access control (RBAC) and auditable activity logs. AnyInsight helps organizations protect sensitive data and enforce AI governance across platforms and networks. Enterprises can securely and rapidly connect their data and business applications, adopt AI agents and automated workflows to boost productivity and knowledge management, and keep complete records ready for compliance audits.

AnyInsight is certified to ISO/IEC 27001:2022 for information security management, and its AI governance and data protection mechanisms are designed on the principles of the EU AI Act and the General Data Protection Regulation (GDPR).

More information: AnyInsight | HEARTBOT AI

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/heartbot-ai-wins-chunghwa-telecom-special-award-at-meet-neo-star-2026-302947562.html

SOURCE HEARTBOT AI Inc.

Continue Reading

Trending